Merck & Co. Issues Forward-Looking statement Amidst Evolving Market Conditions
Kenilworth, NJ – [Current Date] – Merck & Co., Inc., Kenilworth, NJ, USA, has reiterated its commitment to transparency by providing a comprehensive forward-looking statement, a standard practice for publicly traded companies navigating the complexities of the pharmaceutical industry. This statement, grounded in the company’s current understanding of its business adn market dynamics, serves to inform stakeholders about potential future outcomes while acknowledging inherent uncertainties.
The company’s forward-looking statements are formulated in accordance with the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based on the present beliefs and expectations of Merck’s management. However, the company emphasizes that there are no guarantees regarding the regulatory approval or commercial success of its pipeline products. Should the underlying assumptions prove to be inaccurate, or if unforeseen risks and uncertainties materialize, the actual results could diverge substantially from those projected in these forward-looking statements.
Merck’s management acknowledges a broad spectrum of risks and uncertainties that could impact future performance. These include, but are not limited to, general industry conditions and competitive pressures, fluctuations in economic factors such as interest rates and currency exchange rates, and the impact of pharmaceutical industry regulations and healthcare legislation both domestically and internationally. Global trends toward healthcare cost containment, technological advancements, and the introduction of new products and patents by competitors also present potential challenges. Moreover, the company faces inherent difficulties in new product development, including the process of obtaining regulatory approval. Merck’s ability to accurately forecast future market conditions, potential manufacturing delays, and the financial stability of international economies and sovereign risks are also key considerations. The company’s reliance on the effectiveness of its patents and other protections for innovative products, and also exposure to litigation, including patent disputes and regulatory actions, are further factors that could influence outcomes.
Merck & Co. has stated that it undertakes no obligation to publicly update any forward-looking statement, whether in response to new information, future events, or any other developments.Investors are advised that additional factors that could cause actual results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and other filings submitted to the Securities and Exchange Commission (SEC), which are accessible via the SEC’s website (www.sec.gov).
In a separate but related statement, Merck has clarified its position on updating information presented on its website. The company asserts that the information contained within its website was current as of its presentation date. Merck assumes no duty to update this information to reflect subsequent developments. Consequently, the company will not be updating the website’s content, and investors are cautioned against relying on the information as current or accurate beyond the original presentation date.
